Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Continued Treatment with Ruxolitinib Provides Additional Hematocrit Control and Spleen Volume Responses in Patients with PV Treated in the RESPONSE Study

Jean-Jacques Kiladjian, MD PhD, Tamás Masszi, MD PhD, Mark M. Jones, MD, Brian Gadbaw, MD, Jingjin Li, PhD, Dany Habr, MD, Alessandro M. Vannucchi, MD, Srdan Verstovsek, MD PhD

Blood (2015) 126 (23): 2804.

https://doi.org/10.1182/blood.V126.23.2804.2804

Published: 2015

Journal Articles

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Yesim Aydinok, Antonis Kattamis, M. Domenica Cappellini, Amal El-Beshlawy, Raffaella Origa, Mohsen Elalfy, Yurdanur Kilinç, Silverio Perrotta, Zeynep Karakas, Vip Viprakasit, Dany Habr, Niculae Constantinovici, Junwu Shen, John B. Porter

Blood (2015) 125 (25): 3868–3877.

https://doi.org/10.1182/blood-2014-07-586677

Published: 2015

Includes: Supplemental data

Journal Articles

Ruxolitinib Efficacy By Hematocrit Control in Patients with Polycythemia Vera: An Analysis of the RESPONSE Trial

Srdan Verstovsek, MD PhD, Jean-Jacques Kiladjian, MD PhD, Ruben Mesa, MD, Mark M Jones, MD, Shui He, PhD, Jingjin Li, PhD, Dany Habr, MD, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 3201.

https://doi.org/10.1182/blood.V124.21.3201.3201

Published: 2014

Journal Articles

Clinical Benefit of Ruxolitinib Treatment after Crossover from Best Available Therapy in Patients with Polycythemia Vera: Analysis of the RESPONSE Trial

Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Martin Griesshammer, MD, Tamas Masszi, MD PhD, Simon Durrant, MD, Francesco Passamonti, MD, Claire N Harrison, DM, FRCP, FRCPath, Fabrizio Pane, MD, Pierre Zachee, MD PhD, Ruben Mesa, MD, Mark M Jones, MD, Shui He, PhD, Jingjin Li, PhD, Dany Habr, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 3181.

https://doi.org/10.1182/blood.V124.21.3181.3181

Published: 2014

Journal Articles

Mathematical Modeling of Patient-Level Hemoglobin Delineates Ruxolitinib’s Complex Mechanism of Action and Quantifies Anemia Risk

Celine Sarr, PhD, Shweta Urva, PhD, Jerry Nedelman, PhD, William Sallas, PhD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Dany Habr, MD, Renaud Capdeville, MD

Blood (2014) 124 (21): 3228.

https://doi.org/10.1182/blood.V124.21.3228.3228

Published: 2014

Journal Articles

Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

Ruben Mesa, MD, Srdan Verstovsek, MD PhD, Jean-Jacques Kiladjian, MD PhD, Martin Griesshammer, MD, Tamas Masszi, MD PhD, Simon Durrant, MD, Francesco Passamonti, MD, Claire N. Harrison, DM, FRCP, FRCPath, Fabrizio Pane, MD, Pierre Zachee, MD PhD, Shui He, PhD, Mark M Jones, MD, Shreekant Parasuraman, PhD, Jingjin Li, PhD, Isabelle Côté, MD, Dany Habr, MD, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 709.

https://doi.org/10.1182/blood.V124.21.709.709

Published: 2014

Journal Articles

Efficacy of Ruxolitinib By Baseline Spleen Volume in Patients with Polycythemia Vera Resistant to or Intolerant of Hydroxyurea

Alessandro M. Vannucchi, MD, Srdan Verstovsek, MD PhD, Mark M Jones, MD, Shui He, PhD, Jingjin Li, PhD, Dany Habr, MD, Jean-Jacques Kiladjian, MD PhD

Blood (2014) 124 (21): 1840.

https://doi.org/10.1182/blood.V124.21.1840.1840

Published: 2014

Journal Articles

A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)

Dudley J. Pennell, John B. Porter, Antonio Piga, Yongrong Lai, Amal El-Beshlawy, Khawla M. Belhoul, Mohsen Elalfy, Akif Yesilipek, Yurdanur Kilinç, Tomasz Lawniczek, Dany Habr, Marianne Weisskopf, Yiyun Zhang, Yesim Aydinok

Blood (2014) 123 (10): 1447–1454.

https://doi.org/10.1182/blood-2013-04-497842

Published: 2014

Includes: Supplemental data

Journal Articles

Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With β-Thalassemia Major: 2-Year Data From The Cordelia Extension

Dudley J Pennell, MD, John B Porter, MD, Antonio Piga, MD, Yongrong Lai, MD, Amal El-Beshlawy, MD, Khawla Belhoul, MD, Mohsen Elalfy, MD, Akif Yesilipek, MD, Yurdanur Kilinç, MD, Antje Wegener, MD, Dany Habr, MD, Junwu Shen, PhD, Yesim Aydinok, MD

Blood (2013) 122 (21): 1018.

https://doi.org/10.1182/blood.V122.21.1018.1018

Published: 2013

Journal Articles

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Yesim Aydinok, MD, Antonis Kattamis, MD, M Domenica Cappellini, MD, Amal El-Beshlawy, MD, Raffaella Origa, MD, Mohsen Elalfy, MD, Yurdanur Kilinç, MD, Silverio Perrotta, MD, Zeynep Karakas, MD, Vip Viprakasit, MD, Dany Habr, MD, Antje Wegener, MD, Junwu Shen, PhD, John B Porter, MD

Blood (2013) 122 (21): 2257.

https://doi.org/10.1182/blood.V122.21.2257.2257

Published: 2013

Journal Articles

Two-Year Renal Hemodynamic Effects of Deferasirox in Patients with Transfusion-Dependent β-Thalassemia

Antonio Piga, MD, Silvia Fracchia, MD, Maria Eliana Lai, MD, M Domenica Cappellini, MD, Dany Habr, MD, Antje Wegener, MD, Emmanuel Bouillaud, MSc, Gian Luca Forni, MD

Blood (2012) 120 (21): 3257.

https://doi.org/10.1182/blood.V120.21.3257.3257

Published: 2012

Journal Articles

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

Ali T Taher, MD, John B Porter, MD, Vip Viprakasit, MD, DPhil, Antonis Kattamis, MD, Suporn Chuncharunee, MD, Pranee Sutcharitchan, MD, Noppadol Siritanaratkul, MD, Renzo Galanello, MD, Zeynep Karakas, MD, Tomasz Lawniczek, MD, Dany Habr, MD, Jacqueline Ros, PhD, Zewen Zhu, M Domenica Cappellini, MD

Blood (2012) 120 (21): 3258.

https://doi.org/10.1182/blood.V120.21.3258.3258

Published: 2012

Journal Articles

A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with β-Thalassemia Major and Iron Overload (CORDELIA).

Dudley J Pennell, MD, John B Porter, MD, Antonio Piga, MD, Yongrong Lai, MD, Amal El-Beshlawy, MD, Khawla Beloul, MD, Mohsen Elalfy, MD, Akif Yesilipek, MD, Yurdanur Kilinç, MD, Tomasz Lawniczek, MD, Dany Habr, MD, Marianne Weisskopf, PhD, Yiyun Zhang, PhD, Yesim Aydinok, MD

Blood (2012) 120 (21): 2124.

https://doi.org/10.1182/blood.V120.21.2124.2124

Published: 2012

Journal Articles

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

Ali T. Taher, John Porter, Vip Viprakasit, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakas, Tomasz Lawniczek, Jacqueline Ros, Yiyun Zhang, Dany Habr, Maria Domenica Cappellini

Blood (2012) 120 (5): 970–977.

https://doi.org/10.1182/blood-2012-02-412692

Published: 2012

Includes: Supplemental data

Journal Articles

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

Ali T Taher, MD, John B. Porter, MD, Vip Viprakasit, MD; DPhil, Antonis Kattamis, MD, Suporn Chuncharunee, MD, Pranee Sutcharitchan, MD, Noppodol Siritanaratkul, MD, Renzo Galanello, MD, Zeynep Karakas, MD, Tomasz Lawniczek, MD, Jacqueline Ros, PhD, Yiyun Zhang, Dany Habr, MD, M. Domenica Cappellini, MD

Blood (2011) 118 (21): 902.

https://doi.org/10.1182/blood.V118.21.902.902

Published: 2011

Journal Articles

Transfused Myelodysplastic Syndromes (MDS) Patients Have Severe Iron Overload and Relevant Improvements in Iron Burden and Liver Function with Deferasirox Treatment: Results From a Pooled Analysis

Norbert Gattermann, MD, Peter L. Greenberg, MD, Akio Urabe, MD, PhD, Dany Habr, MD, Euloge E. Kpamegan, PhD, John B. Porter, MD

Blood (2011) 118 (21): 5019.

https://doi.org/10.1182/blood.V118.21.5019.5019

Published: 2011

Journal Articles

Hematologic Responses in Patients with Aplastic Anemia Treated with Deferasirox: A Post-Hoc Analysis From the EPIC Study

Jong Wook Lee, MD, PhD, Sung-Soo Yoon, MD, PhD, Zhi Xiang Shen, MD, Arnold Ganser, MD, Hui-Chi Hsu, MD, Ali El-Ali, MD, Dany Habr, MD, Bernard Roubert, PhD, John B. Porter, MD, on behalf of the EPIC study investigators

Blood (2011) 118 (21): 1344.

https://doi.org/10.1182/blood.V118.21.1344.1344

Published: 2011

Journal Articles

A Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox Versus Deferoxamine in Patients with Sickle Cell Disease (SCD): 2-Year Results Including Pharmacokinetics (PK) and Safety of Deferasirox with Concomitant Hydroxyurea Therapy

Elliott Vichinsky, MD, Marcela Torres, MD, Jonathan Glass, MD, Caterina P Minniti, MD, Stéphane Barrette, MD, Dany Habr, MD, Nicola Lynch, MS, Yiyun Zhang, Beatrice Files, MD

Blood (2011) 118 (21): 1082.

https://doi.org/10.1182/blood.V118.21.1082.1082

Published: 2011

Journal Articles

Deferasirox Decreases Liver Iron Concentration (LIC) in Transfusional Iron Overloaded Patients with Myelodysplastic Syndromes (MDS), Aplastic Anemia (AA) and Other Rare Anemias: Results From 1-Year Multi-Center, Open-Label Phase II Study

Yutaka Kohgo, MD, PhD, Akio Urabe, MD, PhD, Yurdanur Kilinç, MD, Leyla Agaoglu, MD, Krzysztof Warzocha, MD, Guillermo Sanz, MD, Lay Cheng Lim, MD, Silvia Helou, MD, Dany Habr, MD, Isabelle Malet, PharmD, Sabine Glaser, Wieslaw Wiktor-Jedrzejczak, MD

Blood (2011) 118 (21): 4838.

https://doi.org/10.1182/blood.V118.21.4838.4838

Published: 2011

Journal Articles

Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria

Norbert Gattermann, MD, Carlo Finelli, MD, Matteo Della Porta, MD, Pierre Fenaux, MD, PhD, Michael Stadler, MD, Agnès Guerci-Bresler, MD, Mathias Schmid, MD, Kerry Taylor, MD, Dominique Vassilieff, MD, Dany Habr, MD, Andrea Marcellari, MS, MT(ASCP), Bernard Roubert, PhD, Christian Rose, MD

Blood (2010) 116 (21): 2912.

https://doi.org/10.1182/blood.V116.21.2912.2912

Published: 2010

NARROW

Continued Treatment with Ruxolitinib Provides Additional Hematocrit Control and Spleen Volume Responses in Patients with PV Treated in the RESPONSE Study

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Ruxolitinib Efficacy By Hematocrit Control in Patients with Polycythemia Vera: An Analysis of the RESPONSE Trial

Clinical Benefit of Ruxolitinib Treatment after Crossover from Best Available Therapy in Patients with Polycythemia Vera: Analysis of the RESPONSE Trial

Mathematical Modeling of Patient-Level Hemoglobin Delineates Ruxolitinib’s Complex Mechanism of Action and Quantifies Anemia Risk

Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

Efficacy of Ruxolitinib By Baseline Spleen Volume in Patients with Polycythemia Vera Resistant to or Intolerant of Hydroxyurea

A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)

Deferasirox Compared With Deferoxamine For The Removal Of Cardiac Iron In Patients With β-Thalassemia Major: 2-Year Data From The Cordelia Extension

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

Two-Year Renal Hemodynamic Effects of Deferasirox in Patients with Transfusion-Dependent β-Thalassemia

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with β-Thalassemia Major and Iron Overload (CORDELIA).

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

Transfused Myelodysplastic Syndromes (MDS) Patients Have Severe Iron Overload and Relevant Improvements in Iron Burden and Liver Function with Deferasirox Treatment: Results From a Pooled Analysis

Hematologic Responses in Patients with Aplastic Anemia Treated with Deferasirox: A Post-Hoc Analysis From the EPIC Study

A Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox Versus Deferoxamine in Patients with Sickle Cell Disease (SCD): 2-Year Results Including Pharmacokinetics (PK) and Safety of Deferasirox with Concomitant Hydroxyurea Therapy

Deferasirox Decreases Liver Iron Concentration (LIC) in Transfusional Iron Overloaded Patients with Myelodysplastic Syndromes (MDS), Aplastic Anemia (AA) and Other Rare Anemias: Results From 1-Year Multi-Center, Open-Label Phase II Study

Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only